IDG WeChat qr Code

Strategic Partnerships

The first firm to bring foreign venture capital to China. A global leader in venture capital, private equity and mergers and acquisitions.

Trust

Our investment partners include fund managers, sovereign wealth funds, pension funds, institutional investors, charities, university endowments and more.

Experience

Founded in 1992, IDG Capital has made more than 750 investments in companies in China and around the world.

Track Record

More than 170 successful exits. We funded more than half of all Chinese unicorns in early rounds.

Our Firm

IDG Capital is a leading investment firm, focusing on developing extraordinary companies through our expertise in private equity, venture capital and mergers and acquisitions.

  • Founded:

    1992

  • Investments:

    750+

  • Exits:

    170+

  • ACCUMULATED Assets Under Management:

    $20 billion

Portfolio Spotlight

Castbox
CheHaoDuo
Klaytn
WangLiBao
Ripple
imToken
Coinbase
LIME
Vzoom
GENTLE MONSTER
DEXON
Huixiaoer
Tongbanjie
Testin
High Fidelity
Haiyunshuju
ZEGO
Zmeng
Emicnet
Wondershare Technology Co,.Ltd
Teambition
Bizport
Insta360
Opera Browser
Kr Space
Xiaopeng Automotive
Wish
Shankai Sports
Super Sports
HEYTEA
All Portfolio Companies

Latest News

IDG CAPITAL INVESTS IN CANCER DIAGNOSTICS

CHINA MONEY NETWORK
04.12.2019

IDG Capital joined a $44 million Series B financing round for Creative Biosciences, a Chinese producer of cancer screening and diagnostic kits. The Guangzhou-based company also recently released an early diagnosis kit for colon cancer which the National Medical Products Administration of China approved and licensed in 2018. Creative Biosciences said it is also developing early diagnosis products for lung cancer and bladder cancer tumors. Founded in 2015, Creative Biosciences nod has testing institutes in Guangzhou and Tianjin.

Learn More

IDG CAPITAL-BACKED BIOTECH FIRM RAISES $14.4 MILLION

DEAL STREET ASIA
04.11.2019

EdiGene, a Japanese biotechnology firm that develops genome-editing technologies for therapeutics to treat genetic diseases and cancer, has raised $14.4 million during its Series B round. EdiGene currently has operations in Guangzhou, China and Cambridge, Massachusetts. IDG Capital led EdiGene's Series A funding round in 2018 and also joined another $10 million financing round in 2019.

Learn More
All News